We are at a pivotal moment in understanding and applying glucocorticoid (GC) therapy in critical illness. For decades, clinical practice has been shaped by paradigms from the 1970s and 1980s that primarily defined GCs as anti-inflammatory agents. However, emerging insights from molecular biology and translational research now call for a comprehensive re-evaluation—one that redefines how GC therapy is conceptualized, studied, and applied across critical care and respiratory medicine.
Meduri et al. (Fri,) studied this question.